To investigate the potential relationship between endogenous sex steroids and presence of stress urinary incontinence (SUI).
Introduction
Female stress urinary incontinence (SUI), the most common type of incontinence, is defined as a complaint of involuntary loss of urine with effort or physical exertion, or on sneezing or coughing [1, 2] . Several established risk factors are described in the literature, such as mode of delivery in giving birth, parity, chronic cough, obesity, connective tissue dysfunction and menopause [1, 3, 4] . There is epidemiological evidence from several studies implicating menopause and subsequent oestrogen deficiency in the pathogenesis of a number of urinary complaints, including incontinence. Furthermore, the bladder, urethra and pelvic floor structures related to SUI are influenced by oestrogen [3, 4] . The effect of menopausal hormone therapy on urinary incontinence (UI) symptoms is still a matter of debate. Local administration of oestrogen improves symptoms of incontinence, while the effect of systemic hormone therapy remains unclear [5] . Several studies have reported conflicting results on incontinence and pelvic organ prolapse [6] [7] [8] . The role of circulating endogenous sex steroids in women with SUI is still controversial. Endogenous circulating oestrogens have been correlated positively and negatively with UI in previous research [9] [10] [11] [12] . Ahn et al. [9] reported an inverse correlation of serum oestradiol (E2) levels and urethral hypermobility, a major mechanism underlying SUI, while Bai et al. [10] described a positive correlation between bladder neck hypermobility and SUI [9, 10] . Augoulea et al. [1] reported significantly lower circulating E2 levels in women with SUI compared with women without SUI [1] . By contrast, one Swedish study in >6,000 peri-and postmenopausal women showed that higher circulating oestrogen levels are associated with UI of any type [12] . Others were unable to detect any correlation between incontinence symptoms and E2 levels in postmenopausal women [13] . Because of the age-dependent incidence of UI, menopause has been postulated as one major risk factor, but its clear association with the onset of SUI has not yet been clarified [14] .
The aim of the present study was to compare the levels of endogenous sex steroids between peri-and postmenopausal women with symptomatic SUI and matched continent women. The primary outcome variable of interest was E2 level. We hypothesized that women with SUI would have lower E2 levels compared with healthy controls.
Patients and Methods
The present case-control study was conducted at the Department of General Gynaecology and Gynaecological Oncology at the Medical University of Vienna, with recruitment between December 2015 and December 2016. The study was approved by the ethics committee of Medical University Vienna (EK No.2174/2015) and all participants gave written, informed consent.
Eligible cases were peri-(17%) and mainly postmenopausal (83%) women visiting our tertiary referral urogynaecology unit for SUI symptoms. The control group consisted of healthy periand postmenopausal volunteers with any benign gynaecological disease and without any evidence of UI or female pelvic floor dysfunction. Exclusion criteria to participate for both groups were: premenopausal or unclear menopausal status; pelvic organ prolapse ≥ grade 2; medical history of urgency incontinence (defined as a complaint of involuntary loss of urine associated with urgency); mixed UI (defined as a complaint of involuntary loss of urine associated with urgency and also with effort or physical exertion or on sneezing or coughing) or urgency (defined as complaint of a sudden, compelling desire to pass urine which is difficult to defer); cancer; vaginal bleeding of unclear history; intake of systemic or local hormone treatment (including use of oral contraceptives as well as use of vaginal oestrogens) or intake of selective oestrogen receptor modulators; severe endometriosis; pelvic inflammatory diseases; and inability to read and sign informed consent. The following characteristics were assessed for each patient: age; menopausal age; years from menopause; weight; height; blood pressure; history of hysterectomy; parity and mode of delivery; nicotine abuse and profession.
A thorough history and physical examination was conducted for all patients with verified SUI, including a standardized urogynaecological interview and a complete vaginal and pelvic examination with controlled provocation with 300 mL saline in the bladder, according to the International Continence Society guidelines [15] . SUI was tested and verified using a cough test and a pad test (quantification of the amount of urine lost over the duration of 1 h, by measuring the increase in the weight in the perineal pads used) with a standardized bladder filling [2] . Cough test was graded according to the urinary loss visualized [2, 16] . Pad test was evaluated as positive if the difference in weight was >0.5 g [17] . Urodynamic assessments were not performed. In addition, physical examination, which was performed by doctors, included the Oxford grading scale to assess pelvic floor muscle function [2, 18] . Pelvic floor strength, graded on a six-point scale, was dichotomized into weak (no contraction, flicker or weak tone, or 0-2) and strong (moderate, good or strong, or 3-5).
Women were classified into two groups: those with verified SUI (n = 47) and a continent control group (n = 47).
Each incontinent woman was matched with a continent control, and matching was based on menopausal status, age, parity and body mass index (BMI). Age matching was performed in 5-year intervals. The controls had no history of SUI or urgency incontinence when interviewed and proved continent in a simple cough provocation test with spontaneously filled bladder checked by bladder scanning. The majority of the women in the control group were outpatients undergoing routine gynaecological examination and one-third of these women were scheduled for hysterectomy or dilatation and curettage. All of these women underwent a routine gynaecological examination, and those presenting with signs of pelvic organ prolapse, or who had undergone surgical correction of prolapse, were excluded from the study. BMI was calculated using the formula: weight (kg)/height (m 2 ). Clinical information, including follow-up data, was obtained from the database of the Department of General Gynaecology and Gynaecological Oncology. All patient records were anonymized and de-identified prior to analysis.
An electrochemiluminescence immunoassay was used for the in vitro quantitative determination of circulating sex steroid levels.
Venous blood samples for hormone assay were taken from all cases and controls between 08:00 and 10:00 h during their first visit to the outpatient clinic, after which serum was separated and stored at À70°C. Serum concentrations of follicle-stimulating hormone (FSH), luteinizing hormone (LH), E2, sex hormone-binding globulin (SHBG), testosterone, prolactin, dehydroepiandrosterone sulphate (DHEAS) and androstendion (AEON) were determined by immunoassay using commercial kits, according to the protocols specified by the manufacturer (elecsysâ2010 Systems; Roche Diagnostics International, Basel, Switzerland). Analytical sensitivity and coefficients of variation (CVs) were as follows: for testosterone 0.02 ng/mL and CV 4-8%; for SHBG 0.5 nmol/L and CV 5%; for E2 10 pg/mL and CV 4-8%; for AEON 0.3 ng/mL and CV 5-7%; for FSH 0.1 mU/ mL and CV 7%; for LH 0.1 mU/mL and CV 4%; for DHEAS 0.1 lg/dL and CV 5-8%; and for prolactin 1.00 ng/mL and CV 4-7%, respectively.
Statistical Analysis
The chi-squared test was used for the comparison of categorical variables between the two groups and Student's t-test for continuous variables. For correlation analysis, the Spearman test was used with correlation coefficient. Multivariate stepwise logistic regression (including backward elimination) was performed to identify variables associated with SUI. P values <0.05 were taken to indicate statistical significance. The SPSS system (IBM, Armonk, NY, USA, Version 23) was used for the calculations. A power analysis was conducted using the software GPOWER [19] . To reach a power of 95%, an overall sample size of 84 women was calculated with an a level of 0.05 and an effect size derived from previously reported serum E2 levels of 17.30 (AE8.16) pg/mL for postmenopausal women with SUI and 24.22 pg/mL (AE8.99) for postmenopausal women without SUI [1] . To account for any dropouts and measurement errors we increased the sample size by 10% to a final sample size of 94 women in all.
Results
The present study comprised a cohort of 94 women, of whom 47 had SUI and 47 were healthy women without incontinence or pelvic floor dysfunction.
Participant Characteristics in the SUI Group
The median (range) BMI in the SUI group was 26 (22-38) kg/m 2 and 9/47 women in this group (19%) were classified as obese, 20/47 (43%) were overweight and 18/47 (38%) had a normal BMI. The mean (AESD) score on the Oxford grading scale was 2.35 (AE0.706) and first desire to void occurred at 208 (AE47.07) mL. The clinical characteristics of all study participants are shown in Table 1 . Hypertension and history of hysterectomy were significantly more common in the SUI compared with the control group (P < 0.001; Table 1 ).
Serum Levels of Circulating Sex Steroids
The mean serum steroid hormone values, stratified by presence/absence of SUI, are shown in Table 2 . Women with SUI had significantly lower E2 and AEON levels compared with matched controls (P = 0.048 and P = 0.033, respectively; Table 2 ). There was no statistically significant association between hormone levels and degree of SUI (P > 0.05).
Multiple Logistic Regression Analysis
Multiple logistic regression analysis was conducted in order to define the impact of different variables on SUI. The presence of SUI was defined as the dependent variable. Independent variables included in the model were age, menopausal age, and years to menopause, BMI, parity, E2, testosterone and AEON. After multiple logistic regression analysis the strongest factor associated with SUI was low circulating E2 levels (P = 0.035; Table 3 ).
Discussion
Urinary incontinence affects a large proportion of postmenopausal women and is a major cause of quality-of-life impairment [1] . Sex steroid levels, particularly oestrogens and androgens, change markedly during menopause, and oestrogen deficiency after menopause causes atrophic changes within the urogenital tract and is also associated with urinary symptoms [20] . It remains unclear, however, whether the increasing prevalence of urinary tract symptoms is attributable to the hormonal changes that occur during the menopausal transition or to advancing age.
The aim of the present study was to compare the levels of endogenous sex steroids between peri-and postmenopausal The study showed statistically significantly lower levels of E2 and AEON in peri-and postmenopausal women with SUI compared with the control group. Furthermore, hypertension and history of hysterectomy were significantly more common in the SUI group.
A few studies have investigated circulating endogenous sex steroids as possible risk factors for SUI, but the results of these studies are conflicting. Our data showed significantly lower E2 levels in women with SUI. Similarly, Augoulea et al. [1] reported that women with SUI had lower circulating E2 levels compared with healthy controls. It could be hypothesized that the diminished levels of oestrogens would have a negative impact on the function of the lower urinary tract and continence mechanism. This is supported by the assumption that oestrogen increases urethral closure pressure and improves pressure transmission to the proximal urethra, both promoting continence [3] . Furthermore, the diminished E2 levels observed in the women with SUI in the present study is supported by other clinical studies. Ahn et al. [9] showed an inverse correlation of serum E2 levels and urethral hypermobility, a major mechanism underlying SUI, while Bai et al. [10] described a positive correlation between bladder neck hypermobility and SUI. So far, it is well established that oestrogens can have an important impact on the function of the lower urogenital system and continence mechanisms, affecting the neurological control of micturition, improving the urethral epithelium maturation and urethral pressure profilometry and circulation, and increasing the sensory threshold of the bladder and detrusor muscle relaxation [1, 9] . Consistent with the present findings, it has also been reported that bladder neck hypermobility is associated with a decreased 17ß E2 level [9] . Additionally, several papers have indicated that oestrogen deficiency during menopause can also affect the quality and quantity of collagen in urogenital tissue [21] . Moreover, oestrogen decreases collagen and increases smooth muscle fibres in the bladder wall, which is associated with higher bladder contractility and resting tension [9] .
Contrary to our findings, some studies showed that higher circulating oestrogen levels were associated with UI of any type [13, 22] . Nevertheless, it should be noted that these studies included a mixed cohort of patients with incontinence and not specifically women with SUI. Waetjen et al. [13] , however, did not detect any correlation between incontinence symptoms and E2 levels in postmenopausal women [13] .
Interestingly, the women's health initiative [7] study reported that women receiving hormone therapy ran a higher risk of developing SUI and that hormone supplementation with oestrogen alone led to a higher risk of developing UI than an oestrogen/progestin combination [8] .
The effect of hormone therapy on UI symptoms is still a matter of debate. Cody et al. [6] reviewed oestrogen's utility in the management of UI and studies of both systemic and vaginal oestrogen were included. The authors came to the conclusion that the route of therapy has different effects, as oral systemic oestrogen worsened incontinence, while vaginal oestrogen improved incontinence [6] ; however, this raises the question of why exogenous oestrogens seem to be bad and endogenous oestrogens seem to be good for LUTS. One possible explanation for the different clinical results could be that the distribution of oestrogen receptors in the bladder and pelvic floor changes according to the different menopausal stages, with different responses to exogenous oestrogen therapy. In the present study cohort, however, we excluded women who were receiving exogenous oestrogen supplementation, therefore we can only comment on endogenous hormone levels and LUTS. The association between low endogenous oestrogen and SUI in the present study population might be explained by a hypo-oestrogenic state, which initiates physiological changes in the lower urinary tract, affecting urinary continence. Consistent with this hypothesis, a number of authors postulated that oestrogen increases the urethral pressure transmission to the proximal urethra and the vascular dilatation in periurethral vessel, both factors promoting continence [3, 23] . Further research is needed to determine the specific influence of exogenous and endogenous E2 hormone levels on SUI.
The present study also found that women with SUI were statistically significantly more likely to have hypertension compared with the continent women in the control group. In this study 60% of women with SUI had to take antihypertensive medication. This is consistent with other studies that cite hypertension as a possible risk factor for UI [1, 24] . It is important to mention that management of modifiable risk factors, such as hypertension and obesity, is important in reducing the risk of SUI. Additionally, the present results showed that women with SUI had a significantly greater prevalence of a history of hysterectomy compared with the control group. The association between the removal of the uterus and UI is still a matter of debate, but these findings are supported by a recent study in a large number of women that suggested hysterectomy to be a constitutional risk factor for UI [25] . Outcomes of previous research are, however, conflicting. A meta-analysis, for example, did not find any evidence of different risk for SUI after hysterectomy [26] .
In general, there is little evidence indicating endogenous sex steroid levels as possible risk factors for pelvic floor disorders. Nevertheless, the impact of oestrogen withdrawal in menopause on the development of UI is controversial, with positive as well as negative correlations between endogenous oestrogen and UI being described [13, 18] .
The present study has some limitations. As it was a casecontrol study, a cause and effect relationship was difficult to determine; therefore, we can only comment on associations between hormone levels and risk factors but not on the underlying causality. Furthermore, the mean age of our study population was 67 years, and the women were an average of 15 years from menopause. Aging is a well-known factor affecting pelvic floor and lower urinary tract anatomy and function. Because the mean age of our SUI population was far from menopause, it is difficult to separate the effects of declining oestrogen levels in menopause from advancing age in general.
Despite these limitations and, although future prospective research is still needed, this clinical study is a useful addition to the few existing studies on sex steroid levels and pelvic floor disorders.
In conclusion, the present study showed statistically significantly lower E2 and AEON serum levels in women with SUI compared with continent controls. Low levels of circulating sex steroids might have a negative impact on the function of the lower urinary tract and continence mechanism and are a possible risk factor for SUI. Research on sex steroids and their effects on the urinary tract should be continued.
